ProShares UltraShort NASDAQ Biotechnology
7 hedge funds and large institutions have $1.6M invested in ProShares UltraShort NASDAQ Biotechnology in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
6.94% less ownership
Funds ownership: 15.63% → 8.69% (-6.9%)
30% less funds holding
Funds holding: 10 → 7 (-3)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less capital invested
Capital invested by funds: $3.17M → $1.6M (-$1.57M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$30.1K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$23.3K |
| 3 |
IMC Chicago
Chicago,
Illinois
|
+$15.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$362K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$327K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$265K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$256K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$31.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $637K | -$265K | -6,251 | -27% |
|
|
OMC
2
Old Mission Capital
Chicago,
Illinois
| $556K | -$327K | -7,704 | -34% |
|
|
3
IMC Chicago
Chicago,
Illinois
| $261K | +$15.3K | +362 | +5% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $98K | -$31.5K | -743 | -22% |
|
|
5
UBS Group
Zurich,
Switzerland
| $26K | +$30.1K | +709 | +70,900% |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $20K | +$23.3K | +549 | New |
|
7
Citigroup
New York
| $2K | – | – | – |
|
|
WP
8
WealthSource Partners
San Luis Obispo,
California
| – | -$362K | -8,025 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$256K | -5,671 | Closed |
|
|
CG
10
Cutler Group
San Francisco,
California
| – | -$2K | -50 | Closed |
|
11
Morgan Stanley
New York
| – | -$2K | -49 | Closed |
|
BIS Hedge Fund Activity: Q2 2021 in Review
7 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2021, worth a combined $1.6M — down 50% from $3.17M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BIS and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $30.1K. The largest seller was WealthSource Partners, exiting entirely with an estimated $362K sold.
- 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2021, down from 10 in Q1 2021.
- Funds reported $1.6M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2021, down 50% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2021 and 4 closed out, a net change of -3 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2021 was UBS Group, an estimated $30.1K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2021 was WealthSource Partners, an estimated $362K sold.
Based on aggregated 13F filings for Q2 2021.